Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We had a gain in FTRE, which has continued to rally in Q4. FTRE benefitted from...
— Chris McIntyre
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Fortrea Holdings Inc.
Fortrea helps its biotech and pharmaceutical customers run clinical trials with the goal of winning approval to sell new treatments in the U.S. and other countries. Fortrea helps design...
Spun off from Labcorp in 2023, the clinical trial provider is working through a business turnaround. Its current stock...
Fortrea helps its biotech and pharmaceutical customers to run clinical trials with the goal of receiving marketing authorization in the U.S. and other countries.
More institutional theses from McIntyre Partnerships
QDEL’s biggest news in Q3, or lack thereof, was its decision not to sell the Point-of-Care (POC) segment. While the company...
We also had smaller losses in STHO, STRZ, and SEG. There was only...
SHC saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024.